Methods and materials for treating autoimmune and/or complement mediated diseases and conditions

• US 8,501,705 B2
• Filed: 12/23/2010
• Issued: 08/06/2013
• Est. Priority Date: 09/11/2003
• Status: Active Grant

• Current Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Christadoss, Premkumar, Tuzun, Erdem
• Primary Examiner(s): ZARA, JANE J
• Application Number:
  US12/928,945
• Publication Number:
  US 20110104156A1
• Time in Patent Office: 957 Days
• Field of Search: 435/6, 435/91.1, 435/91.31, 435/455, 514/1, 514/2, 514/44, 536/23.1, 536/24.5, 536/24.31
• US Class Current: 514/44
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 31/713 Double-stranded nucleic acids or oligonucleotides
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C07K 16/18 against material from animals or humans

Abstract

Disclosed are methods for treating an autoimmune and/or complement mediated disease or condition in a subject. The methods include administering to the subject a compound which inhibits the subject'"'"'s classical complement pathway. The methods include administering to the subject a compound which inhibits the subject'"'"'s classical complement pathway. Compositions which include inhibitors of C1q, C1r, C1s, C2 or C4 and a pharmaceutically acceptable excipient are also described.

Claims

1. A method for treating myasthenia gravis in a subject comprising the step of:

administering to the subject a C2 small interfering RNA (siRNA) that inhibits the classical complement pathway.

2. The method of claim 1, wherein the sequence of the C2 small interfering RNA is a sequence having a sequence selected from the group consisting of SEQ ID NOs:

24-25, SEQ ID NOs;

27-28, SEQ ID NOs;

30-31 and SEQ ID NOs;

33-34.

3. The method of claim 1, wherein the C2 siRNA has a sequence of SEQ ID NOs:

30-31.